hVIVO Disease Models
With the evolution of increasingly more virulent viral diseases, increasing complexity of managing chronic diseases, and growing pressure to deliver safer, more effective treatments at a faster pace, current processes are no longer sufficient. You must identify promising drugs sooner with higher confidence. Disease models hold the key.
You need to understand the disease progression and human response in more detail early to improve drug development time, costs and efficiency, including trial design, dosing regimens, and safety profiles. hVIVO Human Disease Models provides that insight, so you can:
- Obtain superior clinical results
- Identify promising drugs faster
- Promote disease understanding and rational drug selection
- Obtain expert designed, efficient studies with on-time delivery
Obtain superior clinical results
With our standardized processes, controlled settings and infection control, pharmaceutical grade viruses, and hVIVO platform, you can monitor the entire disease lifecycle as subjects move from healthy to sick and recover back to healthy again so you can obtain high quality, longitudinal data from the before, during and after phases of disease. These models can be used to study the efficacy of therapies such as antiviral drugs and vaccines as well as novel therapeutic drug classes such as immunomodulators.
Identify promising drugs, sooner
With lower inoculum, optimized symptomology, our human challenge studies are designed to mimic normal disease patterns and hence can provide a greater degree of precision about drug effects, safety profiles and dosing regimens, reducing time to market. With several models available including flu, RSV and HRV, and our library continuing to grow with our asthma model being finalized, you can test a variety of therapies in development.
Promote disease understanding and rational drug selection
Due to the flexibility of our human challenge platform, you can monitor disease progression and host response in real-time.
The volunteer is studied before infection, during infection and after infection of the new drug or biomarker, making the development cycle more iterative and permitting the identification of new targets significantly simpler. This reduces delays and costs due to problems with animal models and traditional human provocation testing- and can help you jumpstart biomarker development and target identification so crucial for late stage clinical trials.
Obtain expert designed, efficient studies delivered on-time and on budget
hVIVO experts have designed more than 46 studies with over 2,200 volunteers, utilizes a standardized study process with a highly successful recruitment organizations and 97% success rate. We have a dedicated project management team and ability to mine 15 years of trial data to better guide you on trial design and ensure your study is delivered ontime.
How We Do It
Our hVIVO human models of disease utilise the ability of challenge agents, such as respiratory viruses, to elicit common self-limiting diseases such as flu, cold and RSV in otherwise healthy volunteers. By watching the entire disease lifecycle as subjects move from healthy to sick and recover back to healthy again, we can obtain high quality, longitudinal data from the before, during and after phases of disease. These models can be used to study the efficacy of new therapies such as antiviral drugs and vaccines and also to study the target disease itself.
We can demonstrate proof of concept for a new investigational drug in a much shorter timeframe and in fewer subjects than traditionally, and crucially before investing in large, expensive field-based studies. hVIVO embraces the whole of our technology platform, from patient recruitment through to biomedical research and accelerated drug development.
The success of our approach relies on carefully selecting human volunteers and monitoring them throughout a disease episode under tightly controlled medical quarantine conditions. In our human challenge studies, healthy volunteers are isolated in our specialist facility and are infected with a suitable respiratory virus, which is manufactured according to the highest pharmaceutical standards. They are then observed for 10 to 17 days typically. During this time, they may be treated with a new drug candidate, or may have already been given a new vaccine.
In addition, the Company often works on virus only research programmes with the intention of simply understanding how a virus and the human body interact with such research programmes holding the potential to lead to exciting new therapeutic discoveries.
“The advantages of a safe, reproducible human model are incalculable. This model permits the relatively quick and efficient study of new therapeutics in humans, and assists in making critical decisions.” American Journal of Respiratory and Critical Care Medicine, 2010
For more information or to make a specific research or collaboration enquiry please use the Contact Us form.